Confluence Investment Management LLC grew its position in Stryker Corporation (NYSE:SYK – Free Report) by 1.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,000 shares of the medical technology company’s stock after purchasing an additional 3,941 shares during the quarter. Confluence Investment Management LLC’s holdings in Stryker were worth $66,746,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Godfrey Financial Associates Inc. bought a new position in Stryker in the 4th quarter worth $26,000. Sankala Group LLC bought a new stake in Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter worth about $28,000. 77.09% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Stryker
Stryker Stock Performance
NYSE:SYK opened at $340.73 on Tuesday. The stock’s fifty day moving average is $317.77 and its 200 day moving average is $334.62. The firm has a market capitalization of $130.62 billion, a PE ratio of 35.31, a PEG ratio of 2.08 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 15.01 earnings per share for the current year.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is 36.48%.
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles
- Five stocks we like better than Stryker
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
